Risk factors for nonrelapse mortality in the multivariate analysis
| . | Hazard ratio (95% CI) . | P value . |
|---|---|---|
| Age, category | ||
| <50 | 1 | Reference |
| ≥50 | 1.93 (1.64-2.28) | <.001 |
| Sex match between recipient and donor | ||
| Female recipient or male to male | 1 | Reference |
| Female to male | 1.01 (0.85-1.20) | .929 |
| Recipient/donor CMV serostatus | ||
| Negative/positive | 1 | Reference |
| Positive/negative | 0.87 (0.66-1.15) | .332 |
| Positive/positive | 1.00 (0.77-1.29) | .984 |
| Letermovir prophylaxis | ||
| No | 1 | Reference |
| Yes | 0.72 (0.52-0.99) | .043 |
| Disease | ||
| AML | 1 | Reference |
| ALL | 0.93 (0.75-1.14) | .467 |
| MDS | 1.30 (1.06-1.60) | .011 |
| CML | 0.84 (0.54-1.31) | .445 |
| ATL | 1.42 (1.01-2.01) | .043 |
| NHL | 1.06 (0.74-1.50) | .755 |
| MPN | 1.28 (0.90-1.81) | .171 |
| DRI | ||
| Low | 1 | Reference |
| Intermediate | 1.12 (0.83-1.61) | .393 |
| High | 1.47 (0.99-2.16) | .051 |
| KPS | ||
| >80% | 1 | Reference |
| ≤80% | 1.35 (1.12-1.62) | .001 |
| HCT-CI | ||
| <2 | 1 | Reference |
| ≥2 | 1.21 (1.04-1.42) | .016 |
| Donor source | ||
| HLA matched related | 1 | Reference |
| HLA 1-antigen-mismatched related | 1.42 (0.91-2.23) | .127 |
| HLA matched unrelated | 1.21 (0.96-1.53) | .107 |
| HLA 1-locus-mismatched unrelated | 1.78 (1.44-2.22) | <.001 |
| Umbilical cord blood | 1.39 (1.00-1.93) | .049 |
| Haploidentical | 1.98 (1.39-2.81) | <.001 |
| Conditioning intensity | ||
| Myeloablative | 1 | Reference |
| Reduced intensity | 0.90 (0.76-1.05) | .180 |
| GVHD prophylaxis | ||
| MTX and CNI | 1 | Reference |
| MMF and CNI | 1.17 (0.90-1.52) | .248 |
| Other | 1.49 (1.10-2.02) | .011 |
| In vivo T-cell depletion | ||
| No | 1 | Reference |
| Yes | 0.96 (0.75-1.24) | .758 |
| Year of HCT | ||
| 2008-2013 | 1 | Reference |
| 2014-2019 | 0.85 (0.73-0.99) | .032 |
| Organ involvement at the development of grade II-IV acute GVHD | ||
| Skin GVHD | ||
| No | 1 | Reference |
| Yes | 1.02 (0.86-1.22) | .812 |
| Lower-gut GVHD | ||
| No | 1 | Reference |
| Yes | 1.37 (1.17-1.61) | <.001 |
| Liver GVHD | ||
| No | 1 | Reference |
| Yes | 2.64 (2.14-3.26) | <.001 |
| Use of systemic steroids | ||
| No | 1 | Reference |
| Yes | 2.51 (1.96-3.20) | <.001 |
| CMV gastroenteritis* | ||
| No | 1 | Reference |
| Yes | 1.89 (1.50-2.39) | <.001 |
| . | Hazard ratio (95% CI) . | P value . |
|---|---|---|
| Age, category | ||
| <50 | 1 | Reference |
| ≥50 | 1.93 (1.64-2.28) | <.001 |
| Sex match between recipient and donor | ||
| Female recipient or male to male | 1 | Reference |
| Female to male | 1.01 (0.85-1.20) | .929 |
| Recipient/donor CMV serostatus | ||
| Negative/positive | 1 | Reference |
| Positive/negative | 0.87 (0.66-1.15) | .332 |
| Positive/positive | 1.00 (0.77-1.29) | .984 |
| Letermovir prophylaxis | ||
| No | 1 | Reference |
| Yes | 0.72 (0.52-0.99) | .043 |
| Disease | ||
| AML | 1 | Reference |
| ALL | 0.93 (0.75-1.14) | .467 |
| MDS | 1.30 (1.06-1.60) | .011 |
| CML | 0.84 (0.54-1.31) | .445 |
| ATL | 1.42 (1.01-2.01) | .043 |
| NHL | 1.06 (0.74-1.50) | .755 |
| MPN | 1.28 (0.90-1.81) | .171 |
| DRI | ||
| Low | 1 | Reference |
| Intermediate | 1.12 (0.83-1.61) | .393 |
| High | 1.47 (0.99-2.16) | .051 |
| KPS | ||
| >80% | 1 | Reference |
| ≤80% | 1.35 (1.12-1.62) | .001 |
| HCT-CI | ||
| <2 | 1 | Reference |
| ≥2 | 1.21 (1.04-1.42) | .016 |
| Donor source | ||
| HLA matched related | 1 | Reference |
| HLA 1-antigen-mismatched related | 1.42 (0.91-2.23) | .127 |
| HLA matched unrelated | 1.21 (0.96-1.53) | .107 |
| HLA 1-locus-mismatched unrelated | 1.78 (1.44-2.22) | <.001 |
| Umbilical cord blood | 1.39 (1.00-1.93) | .049 |
| Haploidentical | 1.98 (1.39-2.81) | <.001 |
| Conditioning intensity | ||
| Myeloablative | 1 | Reference |
| Reduced intensity | 0.90 (0.76-1.05) | .180 |
| GVHD prophylaxis | ||
| MTX and CNI | 1 | Reference |
| MMF and CNI | 1.17 (0.90-1.52) | .248 |
| Other | 1.49 (1.10-2.02) | .011 |
| In vivo T-cell depletion | ||
| No | 1 | Reference |
| Yes | 0.96 (0.75-1.24) | .758 |
| Year of HCT | ||
| 2008-2013 | 1 | Reference |
| 2014-2019 | 0.85 (0.73-0.99) | .032 |
| Organ involvement at the development of grade II-IV acute GVHD | ||
| Skin GVHD | ||
| No | 1 | Reference |
| Yes | 1.02 (0.86-1.22) | .812 |
| Lower-gut GVHD | ||
| No | 1 | Reference |
| Yes | 1.37 (1.17-1.61) | <.001 |
| Liver GVHD | ||
| No | 1 | Reference |
| Yes | 2.64 (2.14-3.26) | <.001 |
| Use of systemic steroids | ||
| No | 1 | Reference |
| Yes | 2.51 (1.96-3.20) | <.001 |
| CMV gastroenteritis* | ||
| No | 1 | Reference |
| Yes | 1.89 (1.50-2.39) | <.001 |
Bold indicates statistical significance.
Time-dependent covariate.